当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CheckMate-067: Raising the Bar for the Next Decade in Oncology
Journal of Clinical Oncology ( IF 45.3 ) Pub Date : 2021-12-02 , DOI: 10.1200/jco.21.02549
Sarah A Weiss 1 , Harriet Kluger 2
Affiliation  

Few effective systemic therapies were available for patients with advanced melanoma until recently, although durable complete responses were achieved in a small percentage of patients treated with high-dose interleukin-2. In 2015, results from the phase III CheckMate-067 trial1 led to US Food and Drug Administration approval of ipilimumab plus nivolumab, the first immune checkpoint inhibitor (ICI) combination for front-line treatment of advanced melanoma.

中文翻译:

CheckMate-067:提高肿瘤学下一个十年的标准

直到最近,对于晚期黑色素瘤患者来说,有效的全身疗法还很少,尽管一小部分接受高剂量白细胞介素-2治疗的患者取得了持久的完全缓解。2015年,III期CheckMate-067试验1的结果导致美国食品和药物管理局批准ipilimumab加nivolumab,这是第一个用于晚期黑色素瘤一线治疗的免疫检查点抑制剂(ICI)组合。
更新日期:2021-12-03
down
wechat
bug